Axsome Therapeutics reported Q2 losses of $(1.54) per share, missing the analyst consensus estimate of $(1.24) by 24.19 percent. This is a 45.28 percent decrease over losses from the same period last year. However, the company reported quarterly sales of $46.70 million, beating the analyst consensus estimate of $40.19 million by 16.20 percent, a 429.48 percent increase over sales from the same period last year.